Company: CERO
Filing Date: 2025-11-20
Form Type: 424B3
Source: 0001213900-25-113117
Chunk: 46

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-11-20
Form: 424B3
Chunk 46
---
5.

On July 18, 2025, 53 shares
of Series C Preferred Stock were converted into 10,600 shares of Common Stock. The conversion ratio was agreed upon by the Company and
investor at a conversion price of $5.00 per share.

As of September 30, 2025,
there were 7 remaining shares of Series C Preferred Stock, which were convertible into approximately 3,977 shares of Common Stock.

<div align='center'>18</div>

Successor Series D Convertible Preferred Stock

On April 22, 2025, the Company
designated 12,500 shares of our authorized and unissued Preferred Stock as Series D Preferred Stock and established the rights, preferences
and privileges of the Series D Preferred Stock pursuant to the Series D Certificate of Designations filed with the Secretary
of State of the State of Delaware, as summarized below. Except as set forth below, the Series D Preferred Stock has terms and provisions
that are substantially the same as those of the Series A Preferred Stock, Series B Preferred Stock and Series C Preferred
Stock.

General. Each share
of Series D Preferred Stock has a stated value of $1,000 per share and, when issued, the Series D Preferred Stock will be fully
paid and non-assessable.

Ranking. The Series D
Preferred Stock, with respect to the payment of dividends, distributions and payments upon the liquidation, dissolution and winding up
of the Company, ranks senior to all capital stock of the Company (including the Series A Preferred Stock and the Series B Preferred
Stock, except for the Series C Preferred Stock, which will rank pari passu) unless the Required Holders (as defined in
the Series D Certificate of Designations) consent to the creation of other capital stock of the Company that is senior or equal in
rank to the Series D Preferred Stock.

Dividends. The holders
of Series D Preferred Stock will be entitled to dividends, on an as-if converted basis, equal to and in the same form as dividends
actually paid on shares of the Company’s Common Stock, when and if actually paid.

Purchase Rights. If
at any time the Company grants, issues or sells any options, convertible securities, or rights to purchase stock, warrants, securities
or other property pro rata to all or substantially all of the record holders of any class of Common Stock (the “Series D Purchase
Rights”), then each holder of Series D Preferred Stock will be entitled to acquire,